Stephen Schutzman, MD
Cardiovascular Disease · Edgewood, KYNPI 1407121601
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (57.8%), travel and lodging and education — rather than concentrated in one kind of arrangement. 25 manufacturers reported payments, led by Abbott at 30.6% of the total. Among cardiovascular disease clinicians in KY with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 291 payments — averaging $57.69 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$5K
- Medtronic$5K
- Abiomed$1K
- Edwards Lifesciences$1K
- Inari Medical, Inc.$766
- Novartis$764
- plus $3K from 19 others
What the payments were for
- Travel & lodging$7,06442%
- Food & beverage$9,70758%
- Education$160%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abbott | 31 | $5,142 |
| Medtronic(2 entities) | 40 | $4,696 |
| Abiomed | 3 | $1,226 |
| Edwards Lifesciences | 6 | $1,101 |
| Inari Medical, Inc. | 6 | $766 |
| Novartis | 56 | $764 |
| Johnson & Johnson | 42 | $668 |
| Pfizer | 28 | $398 |
| Amgen | 21 | $371 |
| Boehringer Ingelheim | 17 | $299 |
| Boston Scientific | 4 | $282 |
| Penumbra, Inc. | 2 | $198 |
| Shockwave Medical, Inc | 1 | $147 |
| Cardiovascular Systems Inc. | 1 | $141 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 6 | $141 |
| Merck | 6 | $110 |
| E.r. Squibb & Sons, L.L.C. | 7 | $96 |
| AstraZeneca | 4 | $55 |
| Amarin Pharma, Inc. | 2 | $38 |
| Acist Medical Systems, Inc. | 1 | $33 |
| Bayer | 2 | $31 |
| Regeneron Healthcare Solutions, Inc. | 2 | $28 |
| Sanofi-aventis U.S. LLC | 1 | $21 |
| Cardiva Medical, Inc. | 1 | $20 |
| Kiniksa Pharmaceuticals, Ltd. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- PERCLOSE PROGLIDE$2,835
- ONYX FRONTIER$1,653
- CoreValve Evolut$1,476
- Impella$1,084
- FLOWTRIEVER CATHETER, S$680
- CT THROMBECTOMY SYSTEM KIT$680
- ESPRIT$440
- JETi All In One Non-Sterile Kit$342
- COROFLOW$252
- Vascular Lithotripsy$147
- Perclose ProStyle$145
- SYMPLICITY G3$144
- PRESSUREWIRE$141
- Coronary Orbital Atherectomy System$141
- Dragonfly OCT$140
- FFRangio$133
- Endurant$133
- Repatha$128
- ABSOLUTE PRO$126
- AVVIGO Guidance System$121
How this compares
$16,787 in reported general payments places this provider in the 90th percentile of 258 cardiovascular disease providers in Kentucky.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 596 | $568,292 |
| XareltoRivaroxaban | 117 | $120,825 |
| EntrestoSacubitril/Valsartan | 79 | $84,193 |
| Repatha SureclickEvolocumab | 83 | $71,449 |
| FarxigaDapagliflozin Propanediol | 75 | $69,650 |
| Praluent PenAlirocumab | 31 | $24,144 |
| JardianceEmpagliflozin | 15 | $22,794 |
| BrilintaTicagrelor | 16 | $14,096 |
| Atorvastatin Calcium | 1,050 | $8,216 |
| Metoprolol Succinate | 632 | $6,179 |
| Carvedilol | 479 | $3,156 |
| Rosuvastatin Calcium | 369 | $3,128 |
| Losartan Potassium | 353 | $3,107 |
| Isosorbide Mononitrate ErIsosorbide Mononitrate | 340 | $2,942 |
| ClopidogrelClopidogrel Bisulfate | 313 | $2,452 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $398 | $568,292596 claims |
| Johnson & JohnsonXarelto | $668 | $120,825117 claims |
| NovartisEntresto | $764 | $84,19379 claims |
| AstraZenecaFarxiga, Brilinta | $55 | $83,74791 claims |
| Boehringer IngelheimJardiance | $299 | $22,79415 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 258 cardiovascular disease providers in Kentucky.
Other cardiovascular disease in Edgewood
- Kevin MillerEdgewood$10K
- Darryl DiasEdgewood$7K
- Amir PirachaLouisville$530K
- Dinesh KalraLouisville$316K
- William SkinnerLexington$312K
- Prabodh MehtaElizabethtown$133K
- John HarrisLouisville$129K
- David MoliternoLexington$115K
- Rohan SamsonLouisville$94K
- Srinivasa AppakonduHazard$91K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.